Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nesiritide - Scios

Drug Profile

Nesiritide - Scios

Alternative Names: Brain natriuretic peptide - Scios; hBNP; JNS004; Natrecor; Noratak

Latest Information Update: 26 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scios
  • Developer Cilag AG; Quintiles Transnational; Scios
  • Class Heart failure therapies; Natriuretic peptides; Nerve tissue proteins
  • Mechanism of Action Diuretics; Guanylate cyclase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • No development reported Cardiomyopathies; Heart failure
  • Discontinued Chronic heart failure; Postoperative hypertension

Most Recent Events

  • 05 Nov 2022 Efficacy data from a phase III ASCEND trial in Heart failure presented at the American Heart Association (ASH-2022)
  • 28 Mar 2020 Updated efficacy data from the phase III ASCEND HF trial in Acute decompensated heart failure presented at the Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology Session (ACC-WCC-2020)
  • 15 Nov 2010 Efficacy and adverse events data from the phase III ASCEND-HF trial in Acute decompensated heart failure presented at the 83rd Annual Scientific Sessions of the American Heart Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top